Akcea Therapeut (NASDAQ:AKCA) Earns Outperform Rating from Analysts at BMO Capital Markets
Equities research analysts at BMO Capital Markets began coverage on shares of Akcea Therapeut (NASDAQ:AKCA) in a research note issued to investors on Tuesday, The Fly reports. The brokerage set an “outperform” rating on the stock.
A number of other research firms also recently commented on AKCA. Stifel Nicolaus started coverage on Akcea Therapeut in a research report on Tuesday. They issued a “buy” rating and a $19.00 target price on the stock. Wells Fargo & Company assumed coverage on Akcea Therapeut in a report on Tuesday. They issued an “outperform” rating on the stock. Finally, Cowen and Company assumed coverage on Akcea Therapeut in a report on Tuesday. They issued an “outperform” rating on the stock.
Akcea Therapeut (AKCA) opened at 14.90 on Tuesday. The company’s market cap is $956.55 million. Akcea Therapeut has a 52-week low of $8.10 and a 52-week high of $16.30. The stock’s 50 day moving average price is $9.17 and its 200-day moving average price is $9.17.
COPYRIGHT VIOLATION WARNING: “Akcea Therapeut (NASDAQ:AKCA) Earns Outperform Rating from Analysts at BMO Capital Markets” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/08/08/akcea-therapeut-nasdaqakca-earns-outperform-rating-from-analysts-at-bmo-capital-markets.html.
In other news, major shareholder Ionis Pharmaceuticals Inc acquired 3,125,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 19th. The shares were purchased at an average price of $8.00 per share, for a total transaction of $25,000,000.00. Following the acquisition, the insider now owns 28,884,540 shares of the company’s stock, valued at $231,076,320. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Akcea Therapeut Company Profile
Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).
Receive News & Ratings for Akcea Therapeut Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeut and related companies with MarketBeat.com's FREE daily email newsletter.